Blend Therapeutics Inc.

134 Coolidge Avenue

Watertown, Massachusetts  02472

Tel: (617) 923-4100


Website:
www.blendtx.com


Information:
info@blendtx.com

Blend Therapeutics Inc.

Flagship Partners:  David Berry, Ed Kania
Initial Investment: 
2012
Status: 
Private

Blend Therapeutics is a biopharmaceutical company discovering new classes of cancer medicines that have unique modes of action to result in drugs with differentiated therapeutic properties. Our proprietary technology, assets and expertise are built around an integrative R&D process that brings together our new-molecule drug discovery engine and our patented nanoparticle engineering platform. Using its drug discovery approach, Blend has created a pipeline of new molecules and is initially focused on developing innovative cancer drugs. The company was founded by three leaders in the fields of chemistry and nanomedicine from the Brigham and Women’s Hospital (BWH)–Harvard Medical School (HMS), and Massachusetts Institute of Technology (MIT): Dr. Omid Farokhzad of BWH–HMS, and Dr. Robert Langer and Dr. Stephen J. Lippard of MIT.

Ed Kania is on the Board of Directors.